Is a junctional nevus cancerous?

In this article, we will look at what is a junctional nevus is and look at its hazard status.
During one online discussion, they wrote this statement
"They say on the Internet that the junctional nevus should be removed – the risk of rebirth is high."

Let's figure it out. Actually:

A junctional nevus is a non-cancerous type of growth made up of melanocytes. Junctional nevi are usually seen in individuals of lighter skin complexion and can be found anywhere on the body. Most junctional nevi are called acquired because they develop in children or young adults.

Junctional nevus is so called because its nevus cells are located on the border between the epidermis (the first layer of skin) and the dermis (the second layer of skin). The name is not at all because it is "on the border between nevus and melanoma", as many unknown authors think on the Internet.
Now considerations on the topic of his "danger" or "safety":

In 2017, a meta-analysis was published in which, according to 38 (!!!) studies have shown that melanoma develops against the background of ANY type of nevi. Congenital, acquired, intradermal, complex, junctional – ANY.

Conclusion: if you have a junctional nevus, the chances of getting melanoma do not increase. Conduct regular checkups, and also show your skin to a doctor once a year.
Subscribe to the newsletter or ask a question
Click to order
Your order
Total: 
Step #1:Leave contact details for delivery and feedback.
Step #2: After adding contacts, you will be taken to the Stripe payment page, where you can pay for mole tracker and delivery in two clicks.
Your Name
Your Email
Your Phone
On the day of payment, we transmit the information to the delivery service. The delivery time to residents of the USA is 3 days, for the whole world - 14-19 days, depending on the recipient's address.
List of literature
  1. Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069–80.
  2. Karjalainen S1, Salo H., Teppo L. Basal cell and squamous cell carcinoma of the skin in Finland. Site distribution and patientsurvival. Int J Dermatol. 1989 Sep; 28(7): 445–50.
  3. Bastiaens MT, Hoefnagel JJ, Bruijn JA et al. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 1998; 110:880–4.
  4. Luz FB, Ferron C., Cardoso GP. Surgical treatment of basal cell carcinoma: an algorithm based on the literature. An Bras Dermatol. 2015 May-Jun; 90(3): 377–83.
  5. Julien Lanoue, Gary Goldenberg. Basal Cell Carcinoma, А Comprehensive Review of Existing and Emerging Nonsurgical Therapies. J Clin Aesthet Dermatol. 2016 May; 9 (5): 26–36.]
  6. Vijlder, H., Sterenborg, H., Neumann, H., Robinson, D., Haas, E. (2012). Light Fractionation Significantly Improves the Response of Superficial Basal Cell Carcinoma to Aminolaevulinic Acid Photodynamic Therapy: Five-year Follow-up of a Randomized, Prospective Trial. Acta Dermato Venereologica, 92 (6), 641–647. doi: 10.2340/00015555-1448
  7. Lehmann, P. (2007). Methyl aminolaevulinate?photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. British Journal of Dermatology, 156(5), 793–801. doi: 10.1111/j.1365-2133.2007.07833.x.
  8. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006 May; 45(5): 489–98.
  9. Wysong, A., Aasi, S. Z., Tang, J. Y. (2013). Update on Metastatic Basal Cell Carcinoma: A Summary of Published Cases From 1981 Through 2011. JAMA Dermatology, 149(5), 615.
  10. Sekulic A, Migden MR, Basset-Seguin N., Garbe C., Gesierich A., Lao CD., Miller C., Mortier L., Murrell DF., Hamid O., Quevedo JF., Hou J., McKenna E., Dimier N., Williams S., Schadendorf D., Hauschild A.; ERIVANCE BCC Investigators.Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: finalupdate of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 May 16; 17(1):3 32. doi: 10.1186/s12885-017-3286-5.
  11. Lear JT., Migden MR., Lewis KD., Chang ALS., Guminski A., Gutzmer R., Dirix L., Combemale P., Stratigos A., Plummer R., Castro H, Yi T., Mone M., Zhou J., Trefzer U., Kaatz M., Loquai C., Kudchadkar R., Sellami D., Dummer R. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.J Eur Acad Dermatol Venereol. 2018 Mar; 32 (3): 372–381. doi: 10.1111/jdv.14542. Epub 2017 Nov 6.
  12. Wieman TJ., Shively EH., Woodcock TM. Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer. N1983; 52 (9): 1583–1585.
  13. Coker DD, Elias EG, Viravathana T, et al. Chemotherapy for metastatic basal cell carcinoma. Arch Dermatol. 1983; 119 (1): 44–50.
  14. Guthrie TH., Jr, McElveen LJ., Porubsky ES., Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985; 55 (8): 1629–1632.
  15. Bason MM., Grant-Kels JM., Govil M. Metastatic basal cell carcinoma: response to chemotherapy. J Am Acad Dermatol. 1990; 22 (5 Pt 2): 905–908.
  16. Khandekar JD. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report of two patients. Arch Dermatol. 1990; 126 (12): 1,660.
  17. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999; 22 (1): 32–34.
  18. Jefford M., Kiffer JD., Somers G., et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004; 74 (8): 704–705.
  19. Moeholt K., Aagaard H., Pfeiffer P., Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma-a review of the literature. Acta Oncol. 1996; 35 (6): 677–682.
  20. Carneiro BA., Watkin WG., Mehta UK., Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006; 24 (4): 396–400.